AstraZeneca Seeks to Improve its Vaccine Plant in Liverpool with £100 Million

AstraZeneca is seeking resources to boost its operations center in Speke, near Liverpool. The United Kingdom awaits a formal request from the British pharmaceutical company that seeks to expand the resources of its vaccine plant , as announced this Thursday by the Financial Times. Specifically, the same magazine pointed out that AstraZeneca could request up to one hundred million pounds sterling in support.

This operation follows the investment that AstraZeneca made in Ireland in September 2021, after considering that Great Britain’s tax rate was “discouraging.” In this direction, the company invested €360 million to launch a next-generation active pharmaceutical ingredient (API) manufacturing plant for small molecules near Dublin.

AstraZeneca’s plans could expand to other centres, including its Macclesfield manufacturing base. Chancellor Jeremy Hunt stated in November that he was setting aside £520m for future health emergencies, as well as ensuring that life sciences was one of five key sectors for the British economy.

Read more about AstraZeneca and find the latest financial news of the day with the Born2Invest mobile app.

AstraZeneca could expand plans to other sites, including its Macclesfield manufacturing base

In December 2023, the company reached an agreement to acquire the entire share capital of the Chinese start-up Gracell Biotechnologies for a price that could reach $1.2 billion. AstraZeneca’s executive vice president of oncology R&D, Susan Galbraith, said that “the acquisition of Gracell will complement the company’s existing capabilities and previous investments in cell therapy.”

In Spain, the British pharmaceutical company announced yesterday that its new European hub will be located in the Estel building in Barcelona . The project expects, beyond hiring a thousand people, an investment of eight hundred million euros in five years. The arrival of the hub to the Catalan capital, scheduled for 2025, has as its main objective research in oncology treatments, rare diseases, vaccines and immunotherapies, among others.

The Anglo-Saxon pharmaceutical company also appointed Laura Colón as the company’s new oncology director in Spain in mid-December. AstraZeneca is a British biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. The company was founded in 1999 as a result of the merger of the Swedish laboratory Astra AB and the British pharmaceutical company Zeneca Group.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us